27.9 C
Vientiane
Friday, September 12, 2025
spot_img
Home Blog Page 509

ICAO ANC Delegation Visits PVG: VariFlight’s TAM Solution Takes Center Stage

SHANGHAI, July 22, 2025 /PRNewswire/ — On July 8, a distinguished delegation from the International Civil Aviation Organization’s (ICAO) Air Navigation Commission (ANC) arrived at Shanghai Pudong International Airport (PVG) for a technical exchange visit. This visit provided a prime opportunity to showcase PVG’s remarkable achievements in digital transformation, with a particular focus on the Total Airport Management (TAM) solution — a groundbreaking intelligent system co-developed by VariFlight and PVG.

Upon arrival, the delegation received an in-depth briefing on PVG’s digital transformation journey, with emphasis on the TAM solution. As an AI-driven, agent-based operational model, the TAM solution seamlessly integrates various aspects of airport management, optimizing resource allocation, streamlining workflows, and enhancing overall operational performance—all critical for large-scale airports like PVG.


The delegation expressed strong interest in and appreciation for the TAM solution’s practical implementation. VariFlight, as the technical provider of TAM, was on hand to offer detailed explanations, demonstrating its deep understanding of the system’s inner workings and its potential for further development.

Mr. Junrong Liang, President of ICAO ANC, emphasized that ICAO closely monitors the development of artificial intelligence (AI) applications in aviation. He encouraged airports to share more digital and intelligent best practices with ICAO ANC, as these could support the development of globally applicable standards in the future.

Following the meeting, the ANC delegation visited the airside operations area of PVG to observe a live demonstration of autonomous baggage tractors. Under the TAM system, the intelligent Surface Management Agent (SURF Agent) and Ground Management Agent (GMAN Agent) enabled real-time collaboration between systems and vehicles, significantly enhancing the safety and efficiency of autonomous ground operations.

Learn more about VariFlight’s innovations in intelligent airport operations and the future of TAM: https://www.variflight.com.

United States to Charge USD 250 Visa Integrity Fee Starting October

United States to Charge USD 250 Visa Integrity Fee Starting October. (Photo credit: Vanguard News)

The United States will begin charging a new USD 250 “Visa Integrity Fee” to most non-immigrant visa applicants from 1 October, as part of a new law signed by President Donald Trump on 4 July.

The legislation, which was drafted earlier this year and approved by the Senate, introduces the additional charge as part of broader immigration and visa policy reforms. Once in effect, the new fee will apply to a wide range of visa categories, including tourist and business (B-1/B-2), student (F and M), work (H-1B and H-4), and exchange visitor (J) visas.

This USD 250 fee will be charged on top of existing visa costs, such as the Machine Readable Visa (MRV) fee, reciprocity fees, and other standard administrative charges. 

It is expected to increase the overall cost of obtaining a U.S. visa for many international travelers.

President Donald Trump displays a signed “Big Beautiful Bill Act” at the White House on 4 July 2025. (Photo credit: Brendan Smialowski / AFP)

Travelers from countries that are part of the U.S. Visa Waiver Program (VWP) will not be affected. Citizens of countries such as Australia, Japan, South Korea, and most European nations can continue to travel to the United States for tourism or business purposes for up to 90 days without a visa, and therefore will not be subject to the new fee.

However, applicants from countries not included in the VWP, including Laos, will be required to pay the full set of visa fees, including the new integrity charge. 

U.S. authorities have not yet clarified whether the new fee will be reviewed or adjusted annually, nor how the revenue from the charge will be used. Further information is expected to be released closer to the implementation date

Tighter Immigration Controls for Lao Nationals

The introduction of the Visa Integrity Fee follows a series of recent policy moves by the Trump administration aimed at tightening immigration controls.

On 4 June, President Trump signed a full travel ban on 12 countries and a partial ban on an additional seven countries, among which Laos. 

The ban fully prohibits travel to the US by nationals of Afghanistan, Myanmar, Chad, the Republic of the Congo, Equatorial Guinea, Eritrea, Haiti, Iran, Libya, Somalia, Sudan, and Yemen. 

Meanwhile, a partial ban on travelers from Burundi, Cuba, Laos, Sierra Leone, Togo, Turkmenistan, and Venezuela, suspends immigrant entry and restricting nonimmigrant visas in the B-1/B-2 (tourist and business), F and M (student), and J (exchange visitor) categories, while allowing limited exceptions for certain temporary work visas.

For Lao nationals, the combined impact proves particularly challenging. Unlike VWP countries, Lao citizens must obtain visas for any US entry regardless of purpose or duration.

Recent Department of Homeland Security data shows Laos recorded a 9.55 percent overstay rate in the B-1/B-2 category.

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

Q2 2025 Highlights 

  • Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year.
  • FY 2025 revenue guidance of $770 million to $800 million is reaffirmed.
  • Gozellix® launched in the U.S. and commercial dose deliveries commenced.
  • Gozellix has been assigned a Level II HCPCS code[1] (effective 1 October 2025), a prerequisite for receiving Transitional Pass-Through payment status.
  • ProstACT™ Global Phase 3 trial milestone – all 30 patients consented for Part 1. Global expansion with regulatory approvals to expand the trial into China, Japan and Canada.

Q2 2025 Revenue (Unaudited)

Revenue $M

Q2 2025

Q2 2024

Variation

Q1 2025

Variation

Group revenue

204

125

63 %

186

10 %

Global Illuccix® revenue

154

123

25 %

151

2 %

RLS revenue[2]

46

33[3]

39 %

 

Commentary and business highlights

Dr. Christian Behrenbruch, Managing Director and Group CEO, Telix, stated, “Dose volumes for Illuccix rose 7% quarter-on-quarter in the U.S., reinforcing the strength of our market position and continued customer demand. Despite emerging competitive pricing pressure, we have effective strategies in place to manage impact to average selling price. This includes the recent launch of Gozellix which has been assigned a HCPCS code, a crucial reimbursement milestone towards pass-through status. We continue to show positive momentum across multiple assets in our therapeutic pipeline, including achievement of a key recruitment milestone in our ProstACT Global Phase 3 trial.”

Therapeutics business

  • TLX591(177Lu-rosopatamab tetraxetan): Telix has consented all 30 patients required to complete Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate. Patients in two of the three arms (abiraterone and enzalutamide as standard of care) have completed dosing. An interim readout of safety and dosimetry will follow the completion of patient dosing, monitoring and data analysis. The trial is proceeding seamlessly into Part 2 at existing ex-U.S. sites and additional regulatory approvals have been obtained to commence the trial in China, Canada and Japan[4].
  • TLX592 (225Ac-PSMA-RADmAb): Telix has submitted a Human Research Ethics Committee (HREC) application in Australia for a Phase 1, first-in-human therapeutic study of a targeted alpha therapy in advanced metastatic castration resistant prostate cancer.
  • TLX101 (131I-iodofalan, or 131I-IPA): Telix received HREC approval in Australia to commence IPAX BrIGHT, an international pivotal trial. An IPAX BrIGHT Clinical Trial Application (CTA) has also been submitted in Europe.
  • TLX250 (177Lu-DOTA-girentuximab): STARLITE-1[5] is enrolling patients. This Phase 1b/2 clinical trial is investigating the use of TLX250 in combination with cabozantinib and nivolumab, in clear cell renal cell carcinoma (ccRCC). Trial submission is in preparation for a pivotal trial of TLX250 as a monotherapy in advanced metastatic ccRCC, initially launching ex-U.S.
  • TLX090 (153Sm-DOTMP): In July, Telix submitted an Investigational New Drug (IND) application for a Phase 1 bridging study for Telix’s therapeutic candidate for the palliation of bone pain in patients with osteoblastic metastatic disease to the bone.

Precision Medicine business

PSMA portfolio (Illuccix and Gozellix):

  • Telix received country-level approvals for Illuccix in France, Finland, Ireland, Sweden, Germany, Portugal, Greece, the Czech Republic, Belgium and Italy in Q2 and is launching on a market-by-market basis, as reimbursement is secured.
  • Telix has completed enrolment of the Illuccix China Phase 3 study[6], which will be used to file a marketing authorization in China in Q4 2025.
  • Telix has received HREC approval in Australia and filed an IND with the FDA in the U.S. for a Phase 3 clinical trial aimed at expanding the label indication for Illuccix and Gozellix. The BiPASS study[7] will evaluate the performance of MRI[8] combined with PSMA PET[9] imaging for detection and diagnosis of prostate cancer, which is designed to reduce the need for invasive biopsies.
  • Telix has submitted a Prior Approval Supplement (PAS) to update the U.S. Prescribing Information for Illuccix. The proposed label expansion includes patient selection for radioligand therapy (RLT) in the pre-taxane setting. The prescribing information is expected to be updated, following FDA’s review of the submission[10].
  • As part of product lifecycle management strategy, Telix announced a novel PET[11] radiochemistry solution based on fluorine-18 (18F)-aluminium fluoride (AlF), branded AlFluor™[12]. The platform technology enables flexible radiolabeling of PSMA[13] with either AlF or gallium-68 (68Ga). As part of the platform’s development, Telix signed a strategic agreement with University Hospital Ghent and Ghent University for a novel [18F]AlF-PSMA-11 targeting agent, including extensive clinical data to enable a U.S. registration trial.

Pixclara®[14] (TLX101-CDx, 18F-floretyrosine or 18F-FET): A successful Type A meeting was held with the FDA on 24 June 2025, to agree on a path forward for resubmitting the New Drug Application (NDA) for Telix’s brain cancer imaging candidate.

Zircaix®[15] (TLX250-CDx, 89Zr-DFO-girentuximab): The Company continues to progress a Biologics License Application (BLA) with the FDA for its kidney cancer PET imaging candidate. The PDUFA[16] date remains 27 August 2025.

Telix Manufacturing Solutions (TMS)

  • Telix announced its Good Manufacturing Practice (GMP) manufacturing facility in Yokohama, Japan. Telix’s first cyclotron facility in the Asia Pacific region represents a significant milestone in the Company’s global manufacturing strategy. It will serve as a hub for commercial and clinical drug product supply, and future research and development in the region.
  • The TMS facility in Brussels South (Seneffe), Belgium, produced its first GMP commercial radiopharmaceutical doses, marking the formal launch of Telix’s radiopharmaceutical manufacturing capability in Europe.

Corporate update

Telix has received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.   

The Company is fully cooperating with the SEC and is in the process of responding to the information request. At this stage, this matter is a fact-finding request. The Company has elected to notify the Australian Securities and Investments Commission of the SEC’s information request. Telix’s policy is not to discuss any details of an ongoing regulatory inquiry.    

The information request from the SEC does not mean that Telix or anyone else has violated United States federal securities laws or that the SEC has a negative opinion of any person, entity or security. We cannot predict when this matter will be resolved or what (if any) action the SEC may take following the conclusion of this investigation. 

While the matter is ongoing, Telix will continue with its clinical development programs relating to its prostate cancer therapy candidates, in the ordinary course of business. The information request does not extend to Telix’s commercial and late-stage precision medicine products including Illuccix, Gozellix, Zircaix, Pixclara and Scintimun®.  

FY 2025 guidance

  • Telix confirms FY 2025 revenue guidance of $770 million to $800 million[17].
  • Guidance reflects revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS[18].
  • Telix confirms research and development (R&D) expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024.

Guidance disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, United Kingdom, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Telix’s prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the FDA[19], and in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the FDA[20].

Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)

Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com

Media Contact 

Eliza Schleifstein
Eliza@schleifsteinpr.com  

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

 

[1] Healthcare Common Procedure Coding System, refer to ASX disclosure 9 July 2025.

[2] Excludes revenue contribution from Illuccix sales.

[3] Revenue from date of RLS acquisition 27 January 2025.

[4] IND approved in China 22 July 2025; Clinical Trial Notification (CTN) approved in Japan 20 June 2025; Clinical Trial Application for Part 2 approved in Canada 22 May 2025.

[5] ClinicalTrials.gov ID: NCT05663710.

[6] Refer to disclosure 13 May 2025.

[7] ClinicalTrials.gov ID: NCT07052214.

[8] Magnetic resonance imaging.

[9] Imaging of prostate-specific membrane antigen with positron emission tomography.

[10] Subsequent to Telix disclosure on 23 June 2025, the FDA reclassified the submission to a PAS. The submission was made 5 June 2025.

[11] Positron Emission Tomography.

[12] Refer to ASX disclosure 20 June 2025.

[13] Prostate-specific membrane antigen.

[14] Brand name subject to final regulatory approval.

[15] Brand name subject to final regulatory approval.

[16] Prescription Drug User Fee Act.   

[17] Refer to ASX disclosures 20 February 2025.

[18] See Guidance Disclaimer for further information.

[19] Telix ASX disclosure 20 December 2021.

[20] Telix ASX disclosure 21 March 2025.

 

Flipster Extends Esports Presence as Official Crypto Exchange Partner of PSG Talon’s League of Legends Team

TAIPEI, July 22, 2025 /PRNewswire/ — Flipster, a global cryptocurrency trading platform, has announced an expanded partnership with PSG TALON, one of Asia’s premier League of Legends teams. As Official Crypto Exchange Partner for the upcoming competitive season, Flipster continues its commitment to shaping the future of competitive gaming through meaningful fan engagement.

Flipster Extends Esports Presence as Official Crypto Exchange Partner of PSG Talon’s League of Legends Team
Flipster Extends Esports Presence as Official Crypto Exchange Partner of PSG Talon’s League of Legends Team

This marks the latest chapter in Flipster’s ongoing collaboration with TALON, which began earlier in May with the team’s Dota 2 roster. With PSG TALON, Flipster enters one of the most-watched esports titles in the world, bringing fans even closer to the action.

At the core of the partnership is a shared focus on access, creativity, and community. A series of bespoke fan experiences is set to bring the world of trading and gaming closer together in ways that are fresh, personal, and engaging.

These experiences include virtual and in-person meet-and-greets with players, one-on-one video calls, and limited-edition collectible cards featuring game-worn items. Fans can also look forward to watching parties during major tournaments, offering immersive ways to connect with both the team and fellow supporters.

“PSG TALON has always played with heart. They’re adventurous, bold, and unafraid to challenge expectations,” said Youngsun Shin, Head of Product and Partnerships at Flipster. “That fearless mindset resonates with us deeply. In crypto, as in esports, it takes grit to go against the grain and build something new. We’re proud to be part of their journey and excited to give fans more ways to experience the game they love.”

“We’re proud to grow our partnership with Flipster,” said Sean Zhang, CEO of TALON. “They bring fresh perspective and genuine care for the fan experience. Together, we’re creating something different, and PSG TALON fans will be the first to feel it.”

“We are delighted to welcome Flipster as the official partner of our PSG TALON League of Legends team. Together, we share a common ambition: to push the boundaries between technology, competition, and fan experience. This partnership reflects our shared desire to innovate, surprise, and strengthen the bond with our community through unique and immersive fan activations,” said Valentin Weller, Head of PSG Esports, Paris Saint-Germain.

Founded in 2023, Flipster is a high-performance crypto trading platform focused on speed, access, and precision. As it scales globally, it continues to support communities at the intersection of technology, finance, and culture, including the fast-evolving world of esports.

About Flipster

Flipster is the zero-friction exchange for crypto traders who demand the ultimate perpetual trading experience. With deep liquidity, ultra-tight spreads, and instant execution, it delivers precision and performance for those who move fast and trade faster.

Learn more at flipster.io or follow X.

About TALON

TALON is a leading esports and entertainment organization headquartered in Hong Kong, with competitive teams and operations across Asia. TALON is known for its dominance in titles such as League of Legends, Dota 2, Arena of Valor, and more, as well as its growing content platform and lifestyle-driven brand collaborations.

METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting

HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ — METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting. The company demonstrated that its proprietary AiLNP platform enables the rapid design of tissue-targeted lipid nanoparticles (LNPs), which exhibit high delivery efficiency, strong tissue specificity, and excellent translatability in non-human primates (NHPs).

Founded in 1978, the Controlled Release Society is the world’s foremost nonprofit scientific organization dedicated to advanced drug delivery. At this year’s meeting, METiS Technologies stood out as the only Chinese biotechnology company participating with a featured poster presentation. Dr. Hongming Chen, Co-founder and Chief R&D Officer of METiS and a Member of the U.S. National Academy of Engineering, together with Dr. Andong Liu, Vice President of METiS, presented the poster titled: “AI-Empowered LNP Discovery for Organ-Targeted RNA Delivery.”

The AiLNP platform is METiS’ proprietary AI-driven system for nucleic acid delivery design. It integrates a de novo lipid generation foundation model, a high-throughput microfluidics-based LNP assembly and screening system, and a large-scale, proprietary lipid library. Collectively, these innovations expand the design space of nanomaterials by over 1,000-fold compared to conventional approaches—effectively overcoming long-standing discovery bottlenecks in the field.

By combining predictive AI models with molecular dynamics simulations, the AiLNP platform provides mechanistic insights into lipid behavior and enables prediction of more than 10 physicochemical parameters. It further allows for rational design and optimization of LNP components and ratios to construct customized, high-performance delivery systems.

Key findings from the poster highlight the platform’s ability to accelerate LNP design cycles while significantly improving discovery speed and quality across multiple tissue targets:

Liver-targeted LNPs developed through AiLNP demonstrated best-in-class performance for gene editing, achieving high efficiency and safety in NHPs. Using CRISPR-Cas9-mediated TTR knockdown as a model, LNP developed by AiLNP achieved ~90% reduction in serum TTR levels with only a transient, mild elevation in liver enzymes.

Lung-targeted LNPs exhibited high delivery efficiency and specificity in rodents, with successful translation to NHPs. At the cellular level, these LNPs transfected a broad range of pulmonary cell types in NHPs—including stem-like cells, alveolar type II cells (>30%), and airway basal cells (>10%) at 1 mg/kg—supporting their potential for durable genetic correction.

METiS’ Musle-targeted LNPs also enabled successful in vivo delivery and gene editing in multiple types of muscle cells in mice.

Muscle: AiLNP identified first-in-class IV-administered skeletal and cardiac muscle targeting LNPs
Muscle: AiLNP identified first-in-class IV-administered skeletal and cardiac muscle targeting LNPs

 “This year’s CRS theme, ‘Next-Generation Delivery Innovation’, reflects the rapid evolution in drug delivery technologies. Among the 410 accepted posters across 12 research tracks, more than 200 focused on nanomedicine, nanodelivery, and gene editing—demonstrating these as the most active areas of exploration,” said Dr. Hongming Chen, Co-founder and Chief R&D Officer of METiS Technologies. “We’re pleased to present our findings at the world’s premier scientific forum for drug delivery and remain committed to pushing the boundaries of LNP discovery.”

Dr. Chris Lai, Co-founder and CEO of METiS, added: “Since day one, METiS has been positioning at the global forefront of AI-powered nanomaterial innovation. We believe nanodelivery is the critical enabler of the next generation of programmable medicines—and that AI will be the key catalyst driving this transformation.”

About METiS Technologies

AI Nanodelivery for a Healthier Future. METiS Technologies is a pioneering TechBio company at the intersection of artificial intelligence and nanomaterial science, focused on transforming the delivery and application of active agents across life forms. Founded by a team of MIT-trained scientists with deep expertise in AI, quantum mechanics, nanomaterials, and advanced drug delivery, the company has developed three proprietary platform technologies, AiLNP – AI platform for nucleic acid delivery system design; AiRNA – AI platform for mRNA sequence optimization; and AiTEM – AI platform for small molecule formulation design.

METiS’ platforms simulate, predict, and interpret nanoscale interactions to enable rational design, optimization, and validation of next-generation nanomaterials and their payloads. By advancing AI-enabled nanotechnology, METiS strives to unlock new therapeutic possibilities across a wide range of diseases, including cancer, metabolic and autoimmune disorders, and neurodegenerative conditions, and improve the health of lives. 

MAWANI Adding the Shipping Service “FRS1” by “CSTAR LINE” to Jeddah Islamic Port

JEDDAH, Saudi Arabia, July 22, 2025 /PRNewswire/ — The Saudi Ports Authority “Mawani” has announced the addition of the new shipping service “FRS1” operated by CSTAR LINE to Jeddah Islamic Port, contributing to enhancing the port’s competitiveness, expanding its maritime service network, supporting its operational efficiency, and reinforcing its standing as a strategic logistics hub on the Red Sea coast.

MAWANI Adding the Shipping Service “FRS1” by “CSTAR LINE” to Jeddah Islamic Port
MAWANI Adding the Shipping Service “FRS1” by “CSTAR LINE” to Jeddah Islamic Port

The new shipping service links Jeddah Islamic Port with five regional and global ports, including Ningbo, Shanghai, and Nansha in China, Aqaba in Jordan, and Ain Sokhna in Egypt, with a handling capacity of up to 2,000 TEUs.

This step aligns with Mawani’s ongoing efforts to improve the Kingdom’s standing in global performance indicators and support national export movement, in line with the objectives of the National Transport and Logistics Strategy, to solidify the Kingdom’s standing as a global logistics hub bridging the three continents.

It is worth noting that Jeddah Islamic Port features a high handling capacity of 130 million tons, and advanced logistics services through 62 multipurpose berths, in addition to several specialized terminals and modern facilities, including two container terminals with a handling capacity of 7.5 million TEUs, two general cargo terminals, two dry docks for ship repair and marine unit maintenance, and a group of marine service berths.

 

Ricoh InnoAI Center Grand Launch Ushering in a New Era for the AI Ecosystem in Asia

HONG KONG, July 22, 2025 /PRNewswire/ — Ricoh Hong Kong Limited today held the grand opening ceremony of the Ricoh InnoAI Center at Cyberport, marking a significant milestone in the development of the local AI innovation ecosystem. The ceremony was officiated by Mr. Ricky Chong, Managing Director of Ricoh Hong Kong; Mr Eric Yu, General Manager, Digital Operations of Ricoh Hong Kong; Dr. Rocky Cheng, CEO of Hong Kong Cyberport Management Company Limited; and Ms. Georgina Chu, Chief Corporate Development Officer of Hong Kong Cyberport Management Company Limited, along with representatives from Ricoh InnoAI’s partner network. The event showcased Ricoh’s strong commitment to advancing AI technology, real-world applications, talent development, and supporting partners in expanding into overseas markets.

The Ricoh InnoAI Strategy is built on a four-pillar framework: Center + Platform + Co-Creation + Ecosystem, forming a comprehensive AI innovation and commercialization ecosystem. The four key components include:

  • InnoAI Center: A physical co-creation space located at Cyberport, providing developers, startups, and enterprise clients with a collaborative environment and sandbox for AI development and application.
  • InnoAI Hub: A RAG-based knowledge management platform developed by Ricoh, enabling enterprises to build AI agents (e.g., for marketing or financial analysis) using their own uploaded data and documents. It also supports low-code development to streamline AI process management.
  • InnoAI Co-Creation: Expert-led collaboration services from Ricoh to help enterprises transform AI technologies into tangible business outcomes—realizing”AI to Business.”
  • InnoAI Program: A comprehensive accelerator program offering funding, technology, sales, and marketing resources to help partners grow rapidly.

Mr. Ricky Chong, Managing Director of Ricoh Hong Kong, stated“The Ricoh InnoAI Strategy is a forward-looking and holistic AI innovation framework. By integrating a physical center, a knowledge platform, co-creation support, and an ecosystem approach, we aim to connect local innovation with APAC markets. Our goal is to drive AI from R&D to commercialization and build a powerful AI ecosystem that positions Hong Kong as a regional innovation hub.”

Ms. Georgina Chu, Chief Corporate Development Officer of Hong Kong Cyberport Management Company Limited, added“The Ricoh InnoAI Center injects powerful momentum into Cyberport’s AI and blockchain ecosystem. We are delighted to witness Ricoh’s forward-looking InnoAI strategy being implemented in Hong Kong. By joining forces to promote AI innovation, R&D, and translation among local startups, we are fostering deep integration of innovation and technology achievements across various industries. This not only accelerates the intelligent upgrade of local industries but also empowers startups to expand into international markets, propelling Hong Kong toward its goal of becoming a global hub for AI and innovation.”

Our Pillars of the Ricoh InnoAI Program:

  1. Technical Support: Backed by Ricoh’s Beijing R&D team and proprietary large language models (LLMs), partners receive world-class AI support to develop breakthrough and practical solutions.
  2. Sales & Marketing Resources: Ricoh’s professional teams help partners craft precise go-to-market strategies and leverage a network of over 30,000 enterprise clients.
  3. Workspace & GPU Resources: The InnoAI Center at Cyberport offers advanced collaboration spaces and high-performance GPU resources to support compute-intensive projects.
  4. Business Development Support: Partners benefit from Ricoh’s exhibitions, product launches, media services, and promotional platforms.

Each partner in the InnoAI Program receives comprehensive support, including dedicated workspace, industry mentorship, strategic collaboration opportunities, expert advice, and marketing resources to accelerate innovation.

Ricoh also launched the InnoAI APAC Super Connector Program to help partners expand into overseas markets, including Australia, Thailand, and Taiwan region. Senior Ricoh executives from 11 cities and countries across the Asia-Pacific region visited Hong Kong this month to engage with local partners and explore cross-border opportunities.

Ricoh Announces AI MFP Upgrade – Driving Enterprise Digital Transformation

InnoAI Linker Launching in August – Seamless Integration with InnoAI Hub

The upgraded InnoAI Linker will officially launch in August, enabling users to transfer documents and data directly from Ricoh AI MFPs to the InnoAI Hub with a single click. The platform’s enhanced eKM (enterprise knowledge management) system now includes advanced data management features for improved knowledge integration and retrieval. These innovations were demonstrated live at the InnoAI Center launch and received strong industry interest.

Ricoh AI Marketplace Now Live – A Go-to-Market Platform for Local Innovation

The Ricoh AI Marketplace is now officially operational, allowing InnoAI partners to connect their AI applications directly to Ricoh AI MFPs. This enables Ricoh customers to experience cutting-edge AI features while providing local innovators with a streamlined go-to-market platform—fostering the AI2B (AI to Business) ecosystem.

Partner Spotlight: Picksos Docufinder AI Solution Debuts

Ricoh InnoAI partner Pickso has launched its “Docufinder” solution on the AI Marketplace. Designed for enterprises, especially SMEs, it uses AI to rapidly classify large volumes of documents, manage departmental access, and deliver smart insights—greatly enhancing document management and collaboration.

Nurturing AI Talent: InnoAI Youth Empowerment Program

Through the InnoAI Youth Empowerment Program, Ricoh is actively cultivating AI talent among Hong Kong students. Interns collaborate with schools, e-commerce support teams, sales, and pre-sales experts to develop AI agents and participate in real-world projects—gaining hands-on experience and preparing to become future AI leaders.

Ricoh will continue to deepen the four pillars of the InnoAI Strategy—Center, Hub, Co-Creation, and Program—driving AI from R&D to commercialization. Through the Ricoh AI Marketplace, AI MFP applications, and youth empowerment initiatives, Ricoh is building an AI ecosystem that integrates innovation, talent, and industry collaboration. By 2026, Ricoh aims to co-create over 50 AI solutions, starting from Hong Kong and expanding across Asia-Pacific, realizing the vision of “AI to Business” and leading the next wave of enterprise digital transformation.

The distinguished officiating guests presided over the ribbon cutting ceremony, including (from left): Mr Eric Yu, General Manager, Digital Operations of Ricoh Hong Kong; Mr. Ricky Chong, Managing Director, Ricoh Hong Kong, Dr. Rocky Cheng, CEO of Hong Kong Cyberport Management Company Limited; Ms. Georgina Chu, Chief Corporate Development Officer of Hong Kong Cyberport Management Company Limited
The distinguished officiating guests presided over the ribbon cutting ceremony, including (from left): Mr Eric Yu, General Manager, Digital Operations of Ricoh Hong Kong; Mr. Ricky Chong, Managing Director, Ricoh Hong Kong, Dr. Rocky Cheng, CEO of Hong Kong Cyberport Management Company Limited; Ms. Georgina Chu, Chief Corporate Development Officer of Hong Kong Cyberport Management Company Limited

About Ricoh Hong Kong Limited

Established in 1963, Ricoh Hong Kong Limited is a trusted leader in digital services and workplace solutions. As a pioneer in digital transformation, Ricoh Hong Kong empowers organizations to work smarter through its Five Areas of Expertise: Hybrid Workplace, Workflow & Automation, Cloud & IT Infrastructure, Cybersecurity, and AI Application.

Driven by innovation and a strong customer focus, Ricoh Hong Kong integrates people and technology to help businesses stay ahead in a rapidly evolving digital landscape. By delivering tailored solutions that enhance productivity, agility, and collaboration, Ricoh supports organizations in navigating change with confidence. With a steadfast commitment to sustainable growth and digital excellence, Ricoh enables companies to focus on forward — empowering them to lead with purpose and thrive in the future of work.

For more information, please visit http://www.ricoh.com.hk

OneConnect Signs Over RMB 200 Million in Overseas Deals, Boosting Global Growth Through Ping An’s Integrated Finance Synergy

SHANGHAI, July 22, 2025 /PRNewswire/ — Since June 2025, OneConnect has secured multiple fin-tech project contracts across international markets including Hong Kong SAR, Southeast Asia, and South Africa, with total contract value exceeding RMB 200 million (USD 28 million). The company continues to expand its roster of strategic global clients, diversify its project portfolio, and gain broader recognition for Ping An’s integrated financial ecosystem capabilities worldwide.

Hong Kong: Billion-RMB SaaS Deployment and First Overseas Application of AI Deepfake Detection

In Hong Kong, OneConnect has deepened cooperation with local banks, signing contracts totaling over RMB 100 million (USD 14 million). Among them, a leading retail bank adopted a SaaS-based eKYC anti-fraud solution that integrates identity authentication, HKID document recognition, deepfake detection, and other core modules. The solution is expected to serve over 70% of Hong Kong’s retail banking customers, marking a breakthrough for OneConnect’s SaaS subscription model in the premium market.

At the same time, the company reached another agreement with a local bank to implement both eKYC and AI deepfake detection. The service covers remote onboarding and identity verification for residents in Hong Kong, Macau, and mainland China—marking the first deployment of AI-powered anti-GenAI technology in an overseas bank.

In addition, OneConnect secured a public sector contract to upgrade the information system of a Hong Kong government department. The project will consolidate various office systems onto a unified platform to improve administrative efficiency and lays the groundwork for future export of “Happy Ping An”-branded digital governance solutions.

Southeast Asia: Core Banking System Deal in Vietnam, Auto Ecosystem Model Expands

Following deployments in Singapore, the Philippines, Malaysia, and the Middle East, OneConnect has reached an agreement on 30th of June with a top-tier Vietnamese bank to implement a core banking project. The project features a significantly higher proportion of product value compared to earlier deals. It will be rolled out firstly in a subsidiary bank and later expanded across the parent institution. Besides of the core banking system, this client also shows its interests in the localization of modules including AI, risk control, lending, and auto finance.

On the same day, OneConnect also reached a strategic agreement with a leading Vietnamese infrastructure and transportation operator to build a localized, one-stop automotive ecosystem. The solution spans auto insurance tech, vehicle finance, post-sales services, big data, and AI applications. The project is positioned as a model for replication across Southeast Asia’s trillion-RMB auto ecosystem market and strengthens the foundation for Ping An’s expansion in overseas auto finance.

South Africa: Expanding Partnership with Old Mutual to Deliver Ping An’s Life Insurance Capabilities

In South Africa, OneConnect has deepened its strategic partnership with Old Mutual, expanding from a single “Life lnsurance Universal Agent” product to a comprehensive life insurance system including customer service platforms and intelligent underwriting and claims processes. Since 2022, the two companies have launched seven phases of the Life lnsurance Universal Agent solution, significantly improving agent productivity and customer conversion rates. As a flagship life insurance solution, Life lnsurance Universal Agent draws on Ping An’s deep operational experience and applies AI and big data to achieve both standardization and localization.

In 2025, senior executives from Old Mutual visited Ping An’s facilities in Zhangjiang and Suzhou to observe call center and customer service operations. These visits led to new agreements around platform-based solutions, highlighting Ping An’s appeal in global life insurance markets and showcasing its ability to transform operational models through technology.

Technology-Driven and Ecosystem-Oriented: Advancing Chinese Fintech on the Global Stage

From Hong Kong SAR to Southeast Asia and Africa, from banking to public services, and from standalone products to full ecosystem partnerships, OneConnect is accelerating the global implementation of its “Platform + Ecosystem” model by leveraging Ping An’s integrated financial resources and technological strengths.

Looking ahead, OneConnect will continue to deliver more intelligent, scenario-based, and SaaS-driven solutions to meet the evolving needs of global financial institutions—driving the global influence of Chinese fintech and contributing to the digital transformation of financial services worldwide.